Kalaris Therapeutics, Inc. KLRS
Set alert
1.99 USD -0.04 -1.78%
As of Nov 2, 2:17 PM ET
1.94 Day range 2.06
1.78 52-week range 11.88
- YTD
- -76.38%
- 1 year
- -60.36%
- Open
- 2.06
- Prev close
- 2.03
- Mkt cap
- 46.54M
- Vol
- 36.54K
- Avg vol
- 68.71K
- EPS
- -2.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.94
- High
- 2.06
3M chart
Signals (13)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| RSI: Oversold | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| RSI: Oversold | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 2 months ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
Financials — quick view
KLRS Revenue — quarterly 0
KLRS Net income — quarterly -11.52M
KLRS EPS — quarterly -0.48
News
- Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75
- Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
- Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) Estimate
- Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened
- KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders
- Kalaris Therapeutics Appoints Liisa Bayko CFO
Your note
Sign in to keep a note on KLRS — it syncs with the Stock Master app.